Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA VP becomes Senate Democratic staffer

Executive Summary

The Democratic staff of the Senate Finance Committee names Pharmaceutical Research & Manufacturers of America VP-Affordability & Access Committee Michelle Easton as chief of the Health & Welfare Team. Easton joined PhRMA in February 2005, heading up the team's public education and advocacy efforts (1"The Pink Sheet" March 14, 2005, p. 3). From 1997-2003, Easton worked for former Sen. John Breaux (D-La.) as legislative director and counsel and as the Senate Aging Committee's staff director. Prior to working for Breaux, Easton worked as healthcare legislative aid to PhRMA CEO Billy Tauzin while he served in Congress...

You may also be interested in...

PhRMA Readies “Access & Affordability” Campaign; PR Overhaul Complete

The Pharmaceutical Research & Manufacturers of America is establishing an internal group on drug access and affordability in preparation for launching a nationwide public educational effort on the theme

BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals

Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.

Boston Scientific TheraSphere Liver Cancer Treatment Succeeds In EPOCH Trial

Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts